首页> 外文期刊>American journal of therapeutics >Patient Characteristics and Outcomes Associated With Nitrovasodilator Use in the Treatment of Acute Heart Failure
【24h】

Patient Characteristics and Outcomes Associated With Nitrovasodilator Use in the Treatment of Acute Heart Failure

机译:与硝烯酶脱胆剂相关的患者特征和结果,用于治疗急性心力衰竭

获取原文
获取原文并翻译 | 示例
           

摘要

Nitrovasodilators (NVs) are commonly recommended for the treatment of acute heart failure (AHF); however, registries suggest their use is not common. The objectives of this study were to determine patient characteristics associated with NV use and to explore the association between NV use and outcomes [length of stay (LoS) and inpatient mortality] in patients with AHF. A survey of US physicians (n = 426) who treat at least = AHF patients per month with NV provided a patient sample (n = 812 treated with NV and n = 322 not-NV) derived from chart review. Factors associated with NV use as well as patient characteristics and outcomes associated with NV use were explored using bivariate analysis, logistic regression, and negative binomial regression as appropriate. NV-treated patients were more likely to be female, have a higher systolic blood pressure, higher B-type natriuretic peptide and troponin, and stay in the intensive care unit while hospitalized, but less likely to be hyponatremic or hospitalized once previously. Overall, average LoS was 5.10 days (SD = 4.52) with 5.21 days (SD = 0.15) for the NV group and 4.94 days (SD = 0.31) for the non-NV group. The overall inpatient mortality rate was 2.1%. Among physicians who frequently use NV to treat AHF patients, there are distinct patient characteristics between NV treated and nontreated patients, suggesting a phenotype-driven approach. However, no differences in LoS or mortality were observed.
机译:亚硝化酶(NVS)通常推荐用于治疗急性心力衰竭(AHF);但是,注册表表明他们的使用并不常见。本研究的目的是确定与NV使用相关的患者特征,并探讨AHF患者的NV使用和结果[保持率(LOS)和住院性死亡率之间的关联。对美国医生(n = 426)的调查,其每月治疗每月每月患者NV,提供了患者样品(N = 812,NV和N = 322 NOT-NV)的患者样品(n = 812)衍生自图表审查。使用双变量分析,逻辑回归和负二进制回归探索与NV使用的因素以及与NV使用相关的患者特征和结果。 NV治疗的患者更容易成为女性,具有更高的收缩压,更高的B型利钠肽和肌钙蛋白,并在住院时留在重症监护病房中,但前面不太可能是下注或治疗曾经服用过度的。总体而言,平均LOS为5.10天(SD = 4.52),NV组为5.21天(SD = 0.15),为非NV组为4.94天(SD = 0.31)。整体住院死亡率为2.1%。在经常使用NV治疗AHF患者的医生中,NV处理和非生成患者之间存在明显的患者特征,表明一种表型驱动方法。但是,没有观察到LOS或死亡率的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号